Health Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Acorda Therapeutics, Inc.

Acorda Therapeutics Reports First Quarter 2009 Financial Results

“I am pleased that we were able to work quickly to address the comments from the FDA and resubmit our NDA, approximately three weeks from having received the Refuse to File letter on our initial NDA submission, and that the FDA accepted the filing two weeks later,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “We are also encouraged that the FDA has elected to assign Priority Review status to the Fampridine-SR NDA. Our focus in the coming months is to work with the FDA during the regulatory review of Fampridine-SR, to prepare for its launch in the...

• View Other Issues of Health Business Week
  
• View Other NewsRx Publications